Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05791201 · ClinicalTrials.gov registry record · Phase 1
A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes
A Phase 1 study of Type 1 Diabetes, sponsored by Vertex Pharmaceuticals Incorporated.
- Active
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
- 16
- Study locations
NCT05791201 is a Phase 1 study of Type 1 Diabetes that is active but no longer recruiting, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 7 participants, below the 824-participant average among 178 other Type 1 Diabetes trials with a reported enrollment target (99% lower). The trial reports 16 study locations across 6 states.
The verdict
NCT05791201, a Phase 1 study of Type 1 Diabetes, is active but no longer recruiting, sponsored by Vertex Pharmaceuticals Incorporated.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
- 16
- Study locations
Study Summary
The purpose of the study is to evaluate the safety, tolerability, and efficacy of VX-264 in participants with type 1 diabetes (T1D).
Conditions Studied
Interventions
- DRUG VX-264
Study Locations (16)
Other
- University of Alberta, Edmonton - Edmonton
- Montreal Clinical Research Institute - Montreal
- Toronto General Hospital (TGH) - Toronto
- Vancouver General Hospital - Vancouver
- Dresden Center for Islet Transplantation - Dresden
- IRCCS Ospedale San Raffaele - Milan
- Leiden University - Leiden
- Hopiteaux Universitaires de Geneve - Geneva
- Churchill Hospital - Headington
- Royal Victoria Infirmary - Newcastle upon Tyne
Pennsylvania
- Hospital of the University of Pennsylvania - Philadelphia
- University of Pittsburgh Medical Center Montefiore - Pittsburgh
Florida
- UHealth Diabetes Research Institute - Miami
Illinois
- University of Chicago - Chicago
Massachusetts
- Massachusetts General Hospital - Boston
Wisconsin
- University of Wisconsin - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2023-05-16 |
| Est. Completion | 2026-05-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05791201
The ClinicalTrials.gov registry entry for NCT05791201 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 824-participant average among 178 other Type 1 Diabetes trials with a reported enrollment target (99% lower). The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type 1 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which VX-264 is the first listed.
NCT05791201 reports 16 study locations spanning 6 distinct geographic areas - top geographies include Other, Pennsylvania, Florida.
Frequently Asked Questions
What is clinical trial NCT05791201 about?
NCT05791201 is a clinical study titled "A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes". The purpose of the study is to evaluate the safety, tolerability, and efficacy of VX-264 in participants with type 1 diabetes (T1D).
What is the current status of trial NCT05791201?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2023-05-16. Estimated completion is 2026-05-29.
What conditions does trial NCT05791201 study?
This clinical trial studies the following conditions: Type 1 Diabetes.
What interventions are being tested in trial NCT05791201?
The interventions under investigation include: VX-264 (DRUG).
Who is sponsoring clinical trial NCT05791201?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05791201 being conducted?
This trial has 16 study locations across Florida, Illinois, Massachusetts, Pennsylvania, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes
RECRUITING · Phase 1
-
A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus
RECRUITING · Phase 1
-
Denosumab for Type 1 Diabetes
RECRUITING · Phase 1
-
A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes
RECRUITING · Phase 1
-
Combination Adjunctive Therapy to Address Multiple Metabolic Imbalances in Type 1 Diabetes
RECRUITING · Phase 1
-
CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.